Xintela AB - Asset Resilience Ratio

Latest as of September 2025: 37.25%

Xintela AB (XINT) has an Asset Resilience Ratio of 37.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Xintela AB carry for a breakdown of total debt and financial obligations.

Liquid Assets

Skr3.38 Million

≈ $363.85K USD Cash + Short-term Investments

Total Assets

Skr9.08 Million

≈ $976.72K USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Xintela AB's Asset Resilience Ratio has changed over time. See XINT net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Xintela AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Xintela AB market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr3.38 Million	37.25%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr3.38 Million	37.25%

Asset Resilience Insights

Very High Liquidity: Xintela AB maintains exceptional liquid asset reserves at 37.25% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Xintela AB Industry Peers by Asset Resilience Ratio

Compare Xintela AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Aktis Oncology, Inc. Common stock NASDAQ:AKTS	Biotechnology	23.64%
Janux Therapeutics Inc NASDAQ:JANX	Biotechnology	91.79%
Neurotech International Ltd AU:NTI	Biotechnology	0.22%
SynCore Biotechnology Co Ltd TWO:4192	Biotechnology	2.58%
Uniqure NV NASDAQ:QURE	Biotechnology	10.94%
Jazz Pharmaceuticals plc F:J7Z	Biotechnology	6.34%
Brainstorm Cell Therapeutics Inc NASDAQ:BCLI	Biotechnology	0.00%
Altimmune Inc NASDAQ:ALT	Biotechnology	82.06%

Annual Asset Resilience Ratio for Xintela AB (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Xintela AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	67.26%	Skr16.68 Million ≈ $1.80 Million	Skr24.80 Million ≈ $2.67 Million	+24.81pp
2023-12-31	42.45%	Skr7.81 Million ≈ $840.37K	Skr18.39 Million ≈ $1.98 Million	+8.42pp
2022-12-31	34.03%	Skr8.34 Million ≈ $897.84K	Skr24.52 Million ≈ $2.64 Million	-14.38pp
2021-12-31	48.41%	Skr11.98 Million ≈ $1.29 Million	Skr24.74 Million ≈ $2.66 Million	-20.85pp
2020-12-31	69.26%	Skr33.60 Million ≈ $3.62 Million	Skr48.51 Million ≈ $5.22 Million	+66.85pp
2019-12-31	2.41%	Skr412.00K ≈ $44.34K	Skr17.09 Million ≈ $1.84 Million	-60.74pp
2018-12-31	63.16%	Skr31.40 Million ≈ $3.38 Million	Skr49.71 Million ≈ $5.35 Million	-13.49pp
2017-12-31	76.65%	Skr21.91 Million ≈ $2.36 Million	Skr28.59 Million ≈ $3.08 Million	-2.93pp
2016-12-31	79.58%	Skr18.98 Million ≈ $2.04 Million	Skr23.85 Million ≈ $2.57 Million	--

pp = percentage points

About Xintela AB

ST:XINT Sweden Biotechnology

Market Cap

$17.71 Million

Skr164.59 Million SEK

Market Cap Rank

#25404 Global

#522 in Sweden

Share Price

Skr0.23

Change (1 day)

-1.68%

52-Week Range

Skr0.21 - Skr0.50

All Time High

Skr8.60